DANVERS, Mass., May 21, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced it has received approval for implementation of a Continuous Access Protocol (CAP) from the Food & Drug Administration (FDA) for RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella® RP (Right Peripheral) System. The CAP will allow Abiomed to continue enrolling up to 22 additional patients at the 15 U.S. investigational sites for a six month period.
Help employers find you! Check out all the jobs and post your resume.
